Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Intermediate hepatocellular carcinoma (BCLC B), drawn from the whole corpus: 12 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No overall survival gain yet shown for TACE combinations.
Which patients should skip embolisation and go straight to systemic therapy.
Liver damage from repeated embolisation limits later treatment options.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
PFS HR ~0.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
PFS HR 0.
PFS HR 0.